Biotech company BioSenic (Euronext Brussels/Paris:BIOS) announced on Friday that it has filed a continuation patent application in the United States to protect the use of arsenic trioxide (ATO) for the prevention and treatment of sepsis syndrome.
This would strengthen BioSenic subsidiary Medsenic's ATO platform targeting the "cytokine storm" in various infections.
The patent covers two main areas of immediate application: immune- and autoimmune-related diseases, including chronic GvHD, systemic sclerosis and systemic lupus erythematosus, and oncology, including acute promyelocytic leukaemia.
BioSenic's long-term goal is to seek market access approvals for its various formulations, optimising the original properties of arsenic salts, alone or in combination.
Dragonfly Therapeutics names new chief financial officer
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
BioSenic expands US patent portfolio for ATO use in sepsis treatment
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP